Arcus Biosciences (NYSE:RCUS - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.17) by $0.14, Zacks reports. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $36.00 million for the quarter, compared to analyst estimates of $29.38 million.
Arcus Biosciences Trading Up 10.2 %
NYSE:RCUS traded up $1.01 during mid-day trading on Friday, hitting $10.89. The company had a trading volume of 1,786,269 shares, compared to its average volume of 958,588. Arcus Biosciences has a fifty-two week low of $9.85 and a fifty-two week high of $20.00. The business's fifty day moving average is $13.37 and its two-hundred day moving average is $15.40. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24. The firm has a market cap of $1.14 billion, a P/E ratio of -3.46 and a beta of 0.84.
Insider Buying and Selling at Arcus Biosciences
In other news, CFO Robert C. Goeltz II sold 3,594 shares of the firm's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total transaction of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares of the company's stock, valued at $902,070. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Terry J. Rosen purchased 19,800 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were acquired at an average cost of $10.18 per share, for a total transaction of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares of the company's stock, valued at $26,001,348.80. This trade represents a 0.78 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company's stock.
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on RCUS. HC Wainwright raised Arcus Biosciences from a "neutral" rating to a "buy" rating and upped their price target for the company from $18.00 to $24.00 in a research note on Wednesday. Morgan Stanley cut their price target on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. Bank of America cut their price target on Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 19th. Finally, Wedbush reaffirmed an "outperform" rating and set a $36.00 price target on shares of Arcus Biosciences in a research note on Thursday, November 7th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $30.25.
Check Out Our Latest Stock Analysis on Arcus Biosciences
About Arcus Biosciences
(
Get Free Report)
Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.
Read More

Before you consider Arcus Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcus Biosciences wasn't on the list.
While Arcus Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.